Carisma Therapeutics (NASDAQ:CARM) has appointed Drs. Scott Friedman and Ira Tabas to its scientific advisory board (SAB). “It is an honor to welcome Dr. Friedman and Dr. Tabas to our SAB,” said Steven...
Mauna Kea Technologies (Euronext Growth:ALMKT), inventor of the world’s first and only real-time in vivo cellular imaging platform, Cellvizio, designed to deliver high-magnification visualization of cellular structures...
Anebulo Pharmaceuticals (NASDAQ:ANEB) has been awarded the first tranche of a two-year, $1.9 million NIDA grant to develop intravenous selonabant for treating acute cannabis-induced toxicity, including CNS depression in...
Clearmind Medicine (NASDAQ:CMND; FSE:CWYO) announced it has filed an additional patent application with the USPTO for the novel proprietary composition of its MEAI compound for treating metabolic syndrome and obesity...
Alto Neuroscience (NYSE:ANRO) announced the completion of enrollment in its Phase 2b study evaluating ALTO-100 in 300 adults with major depressive disorder (MDD) across 34 U.S. sites. The randomized, double-blind...
BerGenBio (OSE:BGBIO) is developing a pipeline of transformative drugs targeting AXL as a cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections.
Profound Medical (NASDAQ:PROF; TSX:PRN) announced that the U.S. Centers for Medicare and Medicaid Services has issued proposed rules establishing, for the first time, a Category 1 CPT code for the Transurethral...
Rainhouse Manufacturing Canada, a well-established North American CNC machining and manufacturing company, emphasized a recent CNN interview with Dr. Sanjay Gupta, which uncovered the real cause of weight-loss drug...
Exscientia plc (NASDAQ:EXAI) announced its use of Amazon Web Services (AWS) artificial intelligence and machine learning services to power its platform for end-to-end drug discovery and automation. Exscientia’s...
Unicycive Therapeutics (NASDAQ:UNCY) announced positive initial results from the patient reported outcome survey conducted during its pivotal clinical trial of oxylanthanum carbonate (OLC) in patients with...